Clinical trial CO43116
A phase Ib/II open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of Mosunetuzumab in combination with Tiragolumab with or without Atezolizumab in patients with relapsed or refractory b-cell non-hodgkin lymphoma
Cancers | |
---|---|
Organ | Non-Hodgkin lymphoma |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Non |
Sponsor | F. Hoffmann-La Roche Ltd |
EudraCT Identifier | 2021-001060-23 |
Inclusion criteria | Participants who have histologically documented FL or DLBCL, that has relapsed or failed to respond to at least two prior systemic treatment regimens, that expresses CD20 as determined by the local laboratory, at least one bi-dimensionally measurable (?1. |
Last update |